Study of REGN1193 in Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 25 May 2016
At a glance
- Drugs Crotedumab (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 10 May 2016 Status changed from completed to discontinued.
- 11 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Nov 2014 New trial record